Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1

Fig. 3

The overall PFS and OS curves show the PFS and OS of all patients reviewed. Group1 = Normal weight HCC patients without HBV infection; Group2 = Normal weight HCC patients combined HBV infection; Group3 = Overweight HCC patients without HBV infection; Group4 = Overweight HCC patients combined HBV infection; PFS = progression-free survival; OS = overall survival

Back to article page